Treatment of delirium in cancer patients with aripiprazole

Treatment of delirium in cancer patients with aripiprazole - Treatment of delirium with aripiprazole

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007326

Enrollment

Registered

2012-02-18

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Interventions

aripiprazole p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with delirium based on the classifications in the diagnostic and statistical manual of mental disorders(DSM-IV)

Exclusion criteria

Exclusion criteria: 1.dementia 2.inability comply with delirium ratings

Design outcomes

Primary

Measure	Time frame
Memorial Delirium Assessment Scale(MDAS) Drug-Induced Extrapyramidal Symptoms Scale(DIEPSS)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026